RT期刊文章SR电子T1 Anti-IL-5 mepolizumab最低限度影响残留血液嗜酸性粒细胞严重哮喘摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 2100935 10.1183/13993003.00935 -2021 A1 Van Hulst,格伦A1 Jorssen,约瑟夫·雅各布斯A1娜塔莉A1 Henket, Moniq188bet官网地址ue A1路易,Renaud A1 Schleich,佛罗伦萨A1, Fabrice A1 Desmet,克利斯朵夫J .年2021 UL //www.qdcxjkg.com/content/early/2021/07/29/13993003.00935 - 2021. -抽象AB中和抗体的细胞因子白介素(IL) 5已经广泛用于严重嗜酸性的控制哮喘。值得注意的是,患者接受中和anti-IL5生物疗法保持非常稳定的人口剩余血液嗜酸性粒细胞。这些残余的嗜酸性粒细胞是否具有特定生物活性的重要性尚未被研究过,但在预测潜在的长期影响IL5中和在病人。解决剩余嗜酸性粒细胞IL5损耗的影响,我们使用一个比较RNA-sequencing方法和嗜酸性粒细胞产生的基因表达程序相比IL5-depleted IL5-replete人类或小鼠主机,在稳态体内和体外刺激后eosinophil-activating alarmin IL33。我们比较严重的过敏患者血液嗜酸性粒细胞嗜酸性哮喘治疗anti-IL5 mepolizumab治疗哮喘病人匹配的健康对照组和接收ige omalizumab疗法。我们做过类似的比较从小鼠骨髓嗜酸性粒细胞IL5基因缺陷或不。我们报告的限制IL5可用性没有引起任何可检测转录响应在稳态剩余嗜酸性粒细胞mepolizumab-treated患者或IL5-deficient老鼠,和影响只有少数基因IL33反应。在一起,这些结果支持了这样的观点,即治疗IL5中和抗体备件循环池剩余嗜酸性粒细胞很大程度上类似于健康的人。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。 Please open or download the PDF to view this article.Conflict of interest: Glenn Van Hulst has nothing to disclose.Conflict of interest: J. Jorssen reports PhD student scholarship from Fonds de la Recherche scientifique (FRS)-FNRS (Belgium).Conflict of interest: N. Jacobs reports consulting fees and lecture fees from GSK, outside the submitted work.Conflict of interest: Monique Henket has nothing to disclose.Conflict of interest: L. Renaud reports grants from GSK, AZ, Novartis, Chiesi and Teva; royalties from patent AU2016328384, CA2997506, EP 3337393, US2020345266; consulting fees and lecture payments from GSK, AZ, Novartis, Sanofi and Chiesi, outside the submitted work.Conflict of interest: F. Schleich reports grants from GSK, Astrazeneca, Teva, Chiesi and Novartis; consulting fees from GSK, Astrazeneca, Amgen, Chiesi and Novartis; lecture payments from GSK, Astrazeneca, Teva, Chiesi and Novartis, outside the submitted work.Conflict of interest: Fabrice Bureau has nothing to disclose.Conflict of interest: C. Desmet reports salary from Fonds de la Reherche Scientifique – FNRS (Belgium), during the submitted work; consulting fees in Advisory Board on eosinophil research from AstraZeneca; lecture fees for presentation at several scientific symposia in Europe on our research on eosinophils from GSK, outside the submitted work.